APL-1
/ Biogen
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 12, 2017
Apellis raises $47M after pulling the plug on an $86M IPO
(FierceBiotech)
- "Apellis Pharmaceuticals raised $47.1 million in venture cash to push its pipeline of treatments for rare diseases...Apellis plans to push...APL-2, into 5 Phase II studies, targeting the rare diseases paroxysmal nocturnal hemoglobinuria, geographic atrophy, refractory myasthenia gravis, neuromyelitis optica and chronic kidney rejection..."
Anticipated new P2 trial • Financing • Complement-mediated Rare Disorders
1 to 1
Of
1
Go to page
1